Overview

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Molecular Mechanisms of Pharmacological Action
Ribavirin
Sofosbuvir